Marvel Biosciences Announces Testing MB-204 on Autism by French University

Calgary, Alberta, February 20, 2024 -  Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBrain Institute, Tours, France. “We are going to...

Marvel Biosciences Announces Non-Brokered Private Placement

Calgary, Alberta, Canada, January 19, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures (each, a “Debenture”).  The closing was comprised of an aggregate of Cdn.$500,000...

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on Tau protein phosphorylation in mice. Abnormal tau phosphorylation is a hallmark of neurodegenerative...

Marvel Biosciences Invited to Test MB-204 on Autism by French University

Calgary, Alberta (November 16, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effects of MB-204 in mouse models of autism. “We are very pleased to have...

Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

Calgary, Alberta (August 22, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving...

Marvel Highlights Key Asset at the 2023 Alzheimer’s Association International

Calgary, Alberta – (July 10,  2023) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has been selected to present the Company’s scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's...

Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204.  “We are pleased...

Marvel Commence Final Study Required Prior to Initiating Human Trials

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.   “This dog study is the last of the two...

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204. “This rat study, along with the GLP study on...

Marvel Biosciences Announces Closing of First Tranche of Debenture Offering

Calgary, Alberta – Marvel Biosciences Corp. ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures (“Debentures”) for gross proceeds of $1,000,000 (the “Private Placement”), subject to final approval of the TSX Venture Exchange.   The Debentures bear interest at the rate of...